Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
UNII 7RN5DR86CK
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Metastases to soft tissue16.22.02.024; 15.09.03.0200.000112%Not Available
Spinal cord neoplasm17.20.01.009; 16.30.01.0090.000112%Not Available
Sarcopenia15.05.06.0040.000168%Not Available
Left atrial dilatation02.04.02.0250.000168%Not Available
Hypercreatinaemia15.05.03.021; 14.11.01.0240.000112%Not Available
Oral mucosal erythema07.05.05.0230.000112%Not Available
Apparent death08.01.03.0620.000112%Not Available
Oncologic complication16.32.03.0250.000112%Not Available
Tumour rupture16.32.03.0330.000112%Not Available
Metastases to pelvis21.07.04.008; 16.22.02.0210.000112%Not Available
Exposed bone in jaw15.02.04.0340.000112%Not Available
Phyllodes tumour16.10.02.002; 21.05.01.0260.000224%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.000224%Not Available
Pelvic cyst21.07.04.010; 16.04.01.0050.000112%Not Available
Clear cell renal cell carcinoma20.01.04.008; 16.08.02.0040.000280%Not Available
Pulmonary pain22.12.01.010--Not Available
Soft tissue sarcoma16.33.01.003; 15.09.03.0210.001959%Not Available
End stage renal disease20.01.03.0190.000112%Not Available
Intracranial mass17.11.01.0170.000112%Not Available
Angiosarcoma metastatic24.03.06.010; 16.16.03.0020.000280%Not Available
Biliary obstruction09.02.02.0050.000112%Not Available
Cardiac dysfunction02.11.01.0040.000280%Not Available
Chondrosarcoma metastatic16.29.04.001; 15.09.03.0230.000112%Not Available
Desmoplastic small round cell tumour16.13.04.007; 07.21.03.0090.000112%Not Available
Fibrosarcoma16.33.03.001; 15.09.03.0030.000112%Not Available
Gait inability17.02.05.069; 08.01.02.011--Not Available
Haemophagocytic lymphohistiocytosis16.32.03.038; 10.02.01.077; 01.05.01.0260.000224%Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
Hepatic cytolysis09.01.07.0360.000224%Not Available
Hyperaesthesia teeth07.09.06.0050.000571%Not Available
The 20th Page    First    Pre   20 21    Next   Last    Total 21 Pages